Back to School: How biopharma can reboot drug development. Access exclusive analysis here

INGN 241: Phase I

In a Phase I study in cancer patients, a

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE